Navigation Links
Vista Partners Updates Coverage on Raptor Pharmaceuticals Corp. (OTC Bulletin Board: RPTP)
Date:7/31/2008

LOS ANGELES, July 31 /PRNewswire/ -- Vista Partners announced today that it has updated coverage on Raptor Pharmaceuticals Corp. "Raptor's drug candidates, which target billion dollar markets, are progressing through the clinic at a rapid pace. The Company will present Phase 2 results for Convivia(TM) sometime in the 3rd quarter of 2008 and we expect FDA approval of Delayed Release (DR) Cysteamine for the treatment of cystinosis in 2010," stated Ross Silver, Director of Research for Vista Partners. For more information and to download the report for free, please visit the Vista Partners website at http://www.vistap.com and click on the "download research" icon.

About Vista Partners:

Vista Partners provides independent, equity research to institutional and individual investors, with a focus on publicly traded small capitalization companies. With offices in Los Angeles and San Francisco, Vista Partners is one of the fastest growing independently owned equity research firms. Vista Partners professional staff has backgrounds in finance, corporate communications and investment banking. More information is available at http://www.vistap.com.

About Raptor:

Raptor Pharmaceuticals Corp. ("Raptor") is a development-stage biopharmaceutical company leveraging novel drug-targeting platforms and reformulated therapeutics to improve treatment outcomes among patients with liver disorders, infectious diseases, cancer, and various orphan indications. The Company's clinical division advances internally developed and in-licensed clinical-stage product candidates towards marketing approval and commercialization and is currently involved in clinical trials in patients with aldehyde dehydrogenase ("ALDH2") deficiency as part of Raptor's Convivia(TM) program and nephropathic cystinosis as part of Raptor's DR Cysteamine program. Raptor's preclinical division
'/>"/>

SOURCE Vista Partners
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. Expiry of Hart-Scott-Rodino Waiting Period for JUVISTA(R) (Human TGF BETA 3)
2. OncoVista, Inc. Closes on $6.8 Million Financing and Acquires Control of a Public Shell Company
3. Synvista Therapeutics to Present at the BIO InvestorForum 2007
4. Synvista Therapeutics to be Featured on Wallst.net
5. Provista Awards Agreement to Spheris
6. Synvista Therapeutics to Develop Topical Formulation of ALT-2074 for the Treatment of Psoriasis
7. Synvista Therapeutics to Present at the 10th Annual BIO CEO & Investor Conference
8. Renovo Announces Results of Latest Phase 2 Studies of JUVISTA(R) (Human Recombinant TGFbeta3)
9. Vista Partners Updates Coverage on Inovio Biomedical Corporation (Amex: INO) With $3.52 Price Target
10. Synvista Therapeutics Highlights Newly Published Data Demonstrating the Value of Haptoglobin Genotype Testing In People with Diabetes
11. Bayer HealthCare Pharmaceuticals Introduces VistaTrak(TM) an Innovative Contrast Media Management System

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2009)...se is available in German . , Whether it,s ...RFID tags (Radio Frequency Identification) are inc...ey make it possible to label objects or goods and ...e appropriate scanner can read and process the dat...xed to goods under production conditions of up to ...
(Date:11/24/2009)... The New York investment bank KTA Capi...has agreed an AU$6.7 mil convertible note private ...private placement was arranged by KTA Capital as N... New York (PRWEB) November ...nk KTA Capital, LLC ("KTA Capital") has ...
(Date:11/24/2009)...AVIK,Iceland,November24/PRNewswire-FirstCall/--deC...ithasreceivednoticefrom,theNasdaqStockMarketthattr...November30,2009andaForm25-NSEwillbefiledwiththe,Se...E,scommonstock,fromlistingonNasdaq,unlessthecompan...el.Thecompanyhasfiledsuchanappeal,which,willstayth...
(Date:11/24/2009)...AVIK,Iceland,November24/PRNewswire-FirstCall/--deC...pprovalofallofits,"firstday"motionsbytheU.S.Bankru...ourt").deCODElastweekfiledavoluntarypetitionfor,re...iththe,BankruptcyCourt. , Theordersissuedbyth...eitsbusinessduringtheChapter11proceedings.Inpartic...
Breaking Biology Technology:Intelligence inside metal components 2KTA Capital Arranges an AU$6.7 Million Private Placement by Neuren Pharmaceuticals 2deCODE Receives Delisting Notice From Nasdaq, Plans to Appeal 2deCODE Receives Delisting Notice From Nasdaq, Plans to Appeal 3deCODE genetics, Inc. Announces Approval of First Day Motions by Bankruptcy Court 2deCODE genetics, Inc. Announces Approval of First Day Motions by Bankruptcy Court 3
...rowth and FDA Approval of Fujifilm CAD,Product Exp...2008 Financial Guid...0:00 a.m. ET, NASHUA, N.H., May 7 iCAD, Inc. (Na...ter-Aided Detection (CAD),solutions for the early ...l,results for the three months ended March 31, 200...
...EBEC CITY, May 7 /PRNewswire-FirstCall/ - AEterna ... biopharmaceutical company focused on,endocrinolog...ting results,for the first quarter ended March 31,...elix: first patients treated in second efficacy tr...hyperplasia (BPH); - AEZS-108: first patients tre...
...es,Holdings, Inc. (Nasdaq: ADLS ), a biopharmaceu...t and commercialization of novel drugs in the,ther... diseases, today,announced its financial results f... loss available to common shareholders for the thr... ($0.09) per share compared to $10.5,million or ($...
Other Biology Technology:iCAD Reports First Quarter 2008 Financial Results 2iCAD Reports First Quarter 2008 Financial Results 3iCAD Reports First Quarter 2008 Financial Results 4iCAD Reports First Quarter 2008 Financial Results 5iCAD Reports First Quarter 2008 Financial Results 6iCAD Reports First Quarter 2008 Financial Results 7iCAD Reports First Quarter 2008 Financial Results 8iCAD Reports First Quarter 2008 Financial Results 9AEterna Zentaris Reports First Quarter 2008 Financial and Operating Results 2AEterna Zentaris Reports First Quarter 2008 Financial and Operating Results 3AEterna Zentaris Reports First Quarter 2008 Financial and Operating Results 4AEterna Zentaris Reports First Quarter 2008 Financial and Operating Results 5AEterna Zentaris Reports First Quarter 2008 Financial and Operating Results 6AEterna Zentaris Reports First Quarter 2008 Financial and Operating Results 7Advanced Life Sciences Announces First Quarter 2008 Financial Results 2Advanced Life Sciences Announces First Quarter 2008 Financial Results 3Advanced Life Sciences Announces First Quarter 2008 Financial Results 4Advanced Life Sciences Announces First Quarter 2008 Financial Results 5Advanced Life Sciences Announces First Quarter 2008 Financial Results 6Advanced Life Sciences Announces First Quarter 2008 Financial Results 7Advanced Life Sciences Announces First Quarter 2008 Financial Results 8Advanced Life Sciences Announces First Quarter 2008 Financial Results 9
(Date:11/24/2009)...cal Toxicology (ACMT) have signed an agreement to ...Medical Toxicology (JMT), the official journal of...usly published by the University of Pennsylvania P... international, peer-reviewed journal, is dedicate... toxicology. The quarterly journal focuses on the...
(Date:11/24/2009)...ecrets of the earth,s history locked in its icy de...le information on the environments that have been ... Now, a team of researchers from nine institutions...10 million dollars by the National Science Foundat...ally. These scientists will drill through the West...
(Date:11/24/2009)...esearch on bacterial communities throughout six la...mporal patterns, suggesting that scientists could ...imate change in the polar regions. The study, publ...l Academy of Sciences Early Edition, shows that b...chronously over time, correlating with seasonal sh...
Breaking Biology News(10 mins):Springer and the American College of Medical Toxicology to work together 2LSU gets to the bottom of things -- in Antarctica 2Researchers establish common seasonal pattern among bacterial communities in Arctic rivers 2Top 10 Food Tips for the Holidays from the National Foundation for Cancer Research 61886 1Top 10 Food Tips for the Holidays from the National Foundation for Cancer Research 61886 2Top 10 Food Tips for the Holidays from the National Foundation for Cancer Research 61886 3Democratic National Committee Chairman Tim Kaines Statement on the Senates Vote to Proceed to Full Floor Debate of Health Insurance Reform Legislation 61882 1Democratic National Committee Chairman Tim Kaines Statement on the Senates Vote to Proceed to Full Floor Debate of Health Insurance Reform Legislation 61882 2ASTMH Symposium Showcases Efforts To Meet the Need for New Medicines to Treat Infectious Diseases in Developing Countries 6448 1ASTMH Symposium Showcases Efforts To Meet the Need for New Medicines to Treat Infectious Diseases in Developing Countries 6448 2ASTMH Symposium Showcases Efforts To Meet the Need for New Medicines to Treat Infectious Diseases in Developing Countries 6448 3
...starved houseplant and flood-covered crops have so...inach and researchers on two continents, potential...nd human health. , The research, which appeared on...by the journal Nature, involved a tandem of basic-...lications, the scientists say. , First, Swedish p...
... elucidate mechanisms of wake-sleep transitions an...ity of Pennsylvania School of Medicine have demons...alled astrocytes are directly involved in regulati...g of the study is that astrocytes modulate the lev... is thought to be important in controlling wake-to...
...cientists at UCSF sheds light on how the odor dete...ir social behavior. , "Understanding how mice pro...es the sense of smell--should provide insight into...use to transform sensory information into behavior...F assistant professor of anatomy. , "There are st...
Other Biology News:Membrane research opens window to benefits for plants, humans 2Membrane research opens window to benefits for plants, humans 3Penn study finds direct role for glial cells in brain cross-talk 2New study examines how sense of smell affects mating and aggression in mice 2
...-house demand is causing shortages in your laborat...ody. This can cause unwanted distractions, problem...r hard work and endeavour! Bring us your idea and ...We work under ISO 9001 quality assurance in design...
...a recombinant preparation of the catalytic subunit...nase is expressed and isolated from the yeast Pich...aration (2). It recognizes the sequence Asp-Asp-As...ysine residue. The enzyme can be used to cleave an...
...-house demand is causing shortages in your laborat...ody. This can cause unwanted distractions, problem...r hard work and endeavour! Bring us your idea and ...We work under ISO 9001 quality assurance in design...
...(rat) - Diluted Antiserum for RIA, Host: Rabbit ...s, Host: Rabbit Antigen sequence: H-Tyr-Lys-Val-...e-Phe-Leu-Phe-Arg-Pro-Arg-Asn-NH 2 For our corres...lease see Neuromedin U-23 (rat) (H-9295) and ([ 1 ...
Biology Products: